APC-366 tryptase inhibitor data

ARRS disclosed positive preliminary results of a Phase IIa trial of APC-366 in 20 patients with mild to moderate asthma, of whom 18 completed the U.K. trial.

All subjects were tested prior to treatment or placebo to establish a baseline for measurement in the double-blind trial. Patients received inhaled doses of 2.5 mg or 5 mg of APC-366 or placebo, three times daily, for a total of 13 doses. Patients were challenged with an inhaled allergen after the 10th dose on day four to measure early and late airway responsiveness, and were challenged with histamine after the last dose on day five to measure hyper-responsiveness. ...